Small Cell Lung Cancer (SCLC)

>

Latest News

"Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option," according to the study authors.
Concurrent Chemoradiation May Improve LS-SCLC Prognosis

May 8th 2025

Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.

"This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population," according to the study authors.
Anlotinib Combo Improves PFS/OS in Extensive-Stage Small Cell Lung Cancer

April 30th 2025

Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC
Chemoimmunotherapy-Enhanced Survival vs Chemotherapy Alone in ES-SCLC

April 27th 2025

"...The reported feasibility and activity of this combination warrant further evaluation in switch maintenance in the metastatic setting or consolidation after definite chemoradiation for patients with limited-stage SCLC," according to the study authors.
Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC

April 25th 2025

Phase 3 data support using twice-daily high-dose thoracic radiotherapy plus concurrent chemotherapy as an alternative therapy for patients with LS-SCLC.
High-Dose Radiotherapy Boosts Survival Without Toxicity Increase in LS-SCLC

April 20th 2025

More News